Blair William & CO Biogen Inc. Transaction History

Blair William & CO

$33.4 Billion
Q3 2024

A detailed history of Blair William & CO transactions in Biogen Inc. stock. As of the latest transaction made, Blair William & CO holds 12,155 shares of BIIB stock, worth $1.92 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

12,155

Previous 13,094 7.17%

Holding current value

$1.92 Million

Previous $3.04 Million 22.37%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$189.07 - $236.8 $177,536 - $222,355	-939 Reduced 7.17%	12,155 $2.36 Million
Q2 2024 Aug 12, 2024	BUY	$190.52 - $236.72 $43,248 - $53,735	227 Added 1.76%	13,094 $3.04 Million
Q1 2024 May 09, 2024	BUY	$212.02 - $267.71 $240,006 - $303,047	1,132 Added 9.65%	12,867 $2.77 Million
Q4 2023 Feb 12, 2024	SELL	$222.59 - $267.94 $531,544 - $639,840	-2,388 Reduced 16.91%	11,735 $3.04 Million
Q3 2023 Nov 09, 2023	BUY	$253.3 - $285.89 $903,774 - $1.02 Million	3,568 Added 33.8%	14,123 $3.63 Million
Q2 2023 Aug 11, 2023	SELL	$275.25 - $318.06 $98,264 - $113,547	-357 Reduced 3.27%	10,555 $3.01 Million
Q1 2023 May 12, 2023	BUY	$256.56 - $292.34 $148,804 - $169,557	580 Added 5.61%	10,912 $3.03 Million
Q4 2022 Feb 10, 2023	SELL	$252.44 - $306.72 $544,260 - $661,288	-2,156 Reduced 17.26%	10,332 $2.86 Million
Q3 2022 Nov 09, 2022	SELL	$194.69 - $268.46 $297,096 - $409,669	-1,526 Reduced 10.89%	12,488 $3.33 Million
Q2 2022 Aug 10, 2022	SELL	$187.54 - $223.02 $96,020 - $114,186	-512 Reduced 3.52%	14,014 $2.86 Million
Q1 2022 May 13, 2022	SELL	$193.77 - $244.14 $627,039 - $790,037	-3,236 Reduced 18.22%	14,526 $3.06 Million
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $912,921 - $1.17 Million	4,077 Added 29.79%	17,762 $4.26 Million
Q3 2021 Nov 12, 2021	BUY	$282.99 - $369.05 $650,028 - $847,707	2,297 Added 20.17%	13,685 $3.87 Million
Q2 2021 Aug 12, 2021	BUY	$259.0 - $414.71 $277,648 - $444,569	1,072 Added 10.39%	11,388 $3.94 Million
Q1 2021 May 13, 2021	BUY	$242.95 - $284.63 $83,574 - $97,912	344 Added 3.45%	10,316 $2.89 Million
Q4 2020 Feb 09, 2021	SELL	$236.26 - $355.63 $97,339 - $146,519	-412 Reduced 3.97%	9,972 $2.44 Million
Q3 2020 Nov 06, 2020	BUY	$264.77 - $305.71 $274,831 - $317,326	1,038 Added 11.11%	10,384 $2.95 Million
Q2 2020 Aug 12, 2020	SELL	$258.66 - $342.55 $14,484 - $19,182	-56 Reduced 0.6%	9,346 $2.5 Million
Q1 2020 May 11, 2020	SELL	$268.85 - $341.04 $669,167 - $848,848	-2,489 Reduced 20.93%	9,402 $2.98 Million
Q4 2019 Feb 13, 2020	BUY	$220.06 - $304.07 $2.62 Million - $3.62 Million	11,891 New	11,891 $3.53 Million
Q3 2019 Nov 12, 2019	SELL	$217.44 - $243.88 $2.23 Million - $2.5 Million	-10,244 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$219.29 - $241.72 $1.09 Million - $1.2 Million	-4,974 Reduced 32.68%	10,244 $0
Q1 2019 May 14, 2019	SELL	$216.71 - $338.96 $311,412 - $487,085	-1,437 Reduced 8.63%	15,218 $3.6 Million
Q4 2018 Feb 14, 2019	SELL	$278.5 - $352.75 $499,629 - $632,833	-1,794 Reduced 9.72%	16,655 $5.01 Million
Q3 2018 Nov 13, 2018	BUY	$293.51 - $383.83 $802,749 - $1.05 Million	2,735 Added 17.4%	18,449 $6.52 Million
Q2 2018 Aug 13, 2018	SELL	$257.52 - $306.91 $2.14 Million - $2.55 Million	-8,323 Reduced 34.63%	15,714 $4.56 Million
Q1 2018 May 15, 2018	SELL	$260.13 - $367.91 $276,258 - $390,720	-1,062 Reduced 4.23%	24,037 $6.58 Million
Q4 2017 Feb 14, 2018	BUY	$307.64 - $344.58 $321,791 - $360,430	1,046 Added 4.35%	25,099 $8 Million
Q3 2017 Nov 13, 2017	BUY	$281.15 - $329.69 $6.76 Million - $7.93 Million	24,053	24,053 $7.53 Million

Others Institutions Holding BIIB

# of Institutions

1,036

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $22.8B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.

Account